- KR₩1tn
- KR₩1tn
- KR₩100bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 196.53 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -74.52% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.52 | ||
| Price to Tang. Book | 6.54 | ||
| Price to Free Cashflow | 15.7 | ||
| Price to Sales | 9.76 | ||
| EV to EBITDA | 13.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 39.25% | ||
| Return on Equity | 56.04% | ||
| Operating Margin | 62.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 3,902.73 | 5,062.38 | 4,950.93 | 34,007.6 | 99,838.67 | 75,000 | 68,000 | 18.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +3812.7 | -58.27 | -84.59 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oscotec Inc is a Korea‑based company primarily engaged in new drug development business. The Company operates four main businesses. The new drug development business primarily mainly researches and develops synthetic new drugs, including therapies for autoimmune diseases, acute myeloid leukemia, refractory solid tumors, Alzheimer’s disease and next‑generation solid tumor treatments designed to overcome drug resistance. The dental bone graft business primarily supplies bone graft materials. The dental barrier membrane business provides own developed absorbable collagen barrier membranes. The functional materials and related products business primarily provide functional materials for osteoporosis prevention and bone health, materials and finished products for arthritis prevention and alleviation, and functional materials for periodontal disease prevention and alleviation.
Directors
- Jeong Geun Kim CEO (53)
- Jong Seong Goh VPR (56)
- Se Won Kim VPR (55)
- Si Yeong Yang VPR (55)
- Chang Nam Kim OTH (53)
- Jung Ho Kim OTH (53)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- December 8th, 1998
- Public Since
- January 17th, 2007
- No. of Shareholders
- 53,420
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 38,258,176
- Address
- A-901, Korea Bio Park, 700,, SEONGNAM, 13488
- Web
- http://www.oscotec.com/
- Phone
- +82 316287613
- Auditors
- Ihnduck Accounting Corp.
Latest News for 039200
Upcoming Events for 039200
Q3 2026 Oscotec Inc Earnings Release
Oscotec Inc Extraordinary Shareholders Meeting
Q4 2026 Oscotec Inc Earnings Release
Oscotec Inc Annual Shareholders Meeting
Similar to 039200
AbClon
Korea Exchange - KOSDAQ
ADBiotech
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
AMINOLOGICS
Korea Exchange - KOSDAQ
FAQ
As of Today at 04:34 UTC, shares in Oscotec are trading at KR₩36,800. This share price information is delayed by 15 minutes.
Shares in Oscotec last closed at KR₩36,800 and the price had moved by -9.94% over the past 365 days. In terms of relative price strength the Oscotec share price has underperformed the FTSE Developed Asia Pacific Index by -34.22% over the past year.
The overall consensus recommendation for Oscotec is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOscotec does not currently pay a dividend.
Oscotec does not currently pay a dividend.
Oscotec does not currently pay a dividend.
To buy shares in Oscotec you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩36,800, shares in Oscotec had a market capitalisation of KR₩1tn.
Here are the trading details for Oscotec:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 039200
Based on an overall assessment of its quality, value and momentum Oscotec is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oscotec is KR₩67,000. That is 82.07% above the last closing price of KR₩36,800.
Analysts covering Oscotec currently have a consensus Earnings Per Share (EPS) forecast of KR₩571 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oscotec. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -35.23%.
As of the last closing price of KR₩36,800, shares in Oscotec were trading -14.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oscotec PE ratio based on its reported earnings over the past 12 months is 196.53. The shares last closed at KR₩36,800.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oscotec's management team is headed by:
- Jeong Geun Kim - CEO
- Jong Seong Goh - VPR
- Se Won Kim - VPR
- Si Yeong Yang - VPR
- Chang Nam Kim - OTH
- Jung Ho Kim - OTH